Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma

NCT03226249 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03226249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03226249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Unknown status
Start date
November 9, 2017
Completion date
October 31, 2024
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma, lymphocyte-depleted classical hodgkin lymphoma, lymphocyte-rich classical hodgkin lymphoma, mixed cellularity classical hodgkin lymphoma, nodular sclerosis classical hodgkin lymphoma